FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					,000011	00(1	1) 01 1110	Investme		mpany 70	51 01 10 10						
Name and Address of Reporting Person*     Biller Scott					2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC AGIO								Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director 10% Owner     Officer (give title Other (specify)				
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET  (Street) CAMBRIDGE MA 02139					3. Date of Earliest Transaction (Month/Day/Year) 02/05/2018  4. If Amendment, Date of Original Filed (Month/Day/Year)								X	below)		below	
													6. Individual or Joint/Group Filing (Check Applicable Line)				
													X	Form filed by More than One Reporting Person			
(Si	tate) (	Zip)															
	Tab	le I -	Non-Deriv	/ative	Sec	urit	ies Ac	quired,	Dis	sposed	of, or B	enefic	ially	Own	ed		
1. Title of Security (Instr. 3)			Date		Execution Date,		3. Transaction Code (Instr. 8)					4 and Secu Bene Own		rities eficially ed	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	nount (A) or Pr		,	Following Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	(Instr. 4)
Common stock 02/05/20				018	18			<b>M</b> <sup>(1)</sup>		64	4 A \$0		1675	53,123		D	
Common stock 02/0:		02/05/20	018			<b>M</b> <sup>(1)</sup>		2,93	6 A	\$9	\$9.05		56,059	D			
Common stock		02/05/2018				S <sup>(2)</sup>		799	D \$74		.89(3)	55,260		D			
Common stock			02/05/20	018			<b>S</b> <sup>(2)</sup>		1,100	0 D	D \$75.		54,160		D		
Common stock 0			02/05/20	018				<b>S</b> <sup>(2)</sup>		701	D	\$76.	.76(5)	53,459		D	
Common stock 02/05/2			)18		S <sup>(2)</sup>		400	D	\$78.	3.03(6)		53,059	D				
	Ta	able I												wned	I		
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year) if a		ition Date,	Code (	5. Num Instr. of Deriv Secu Acqu (A) o Disp of (D (Inst		nber ivative curities quired or posed D)	6. Date Exercis Expiration Date		е	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		of Deri Secu	vative urity	derivative Securities Beneficially Owned Following Reported	Ownership Form: Direct (D) or Indirect (I) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V (A)		(D)				Title	or					
\$0.4675	02/05/2018			M <sup>(1)</sup>			64	(7)	1	2/06/2020	Common stock	64	\$0	0.00	1,803	D	
\$9.05	02/05/2018			M <sup>(1)</sup>			2,936	(8)	0	4/30/2023	Common stock	2,936	\$0	0.00	31,154	D	
	(Fi IOS PHARM IEY STREE  RIDGE M (Si Security (Instance) I stock I sto	(First) (OS PHARMACEUTICALS (EY STREET)  RIDGE MA (State) (OTable Security (Instr. 3)  I stock	(First) (Middle IOS PHARMACEUTICALS, INC IEY STREET  RIDGE MA 02139  (State) (Zip)  Table I -  Security (Instr. 3)  1 stock 1 stock 1 stock 2 stock 2 stock 2 stock 3 stock 4 stock 5 stock 5 stock 6 stock 7 stock 8 stock 9 stock 1 stock 9 stock 1 stock 1 stock 1 stock 1 stock 2 stock 2 stock 3 Table I stock 6 stock 1 stock 9 stock 1 stock 1 stock 1 stock 1 stock 2 stock 2 stock 3 stock 3 stock 6 stock 1 stock 8 stock 9 stock 1 stock 9 stock 1 stock 1 stock 1 stock 1 stock 1 stock 2 stock 1 stock 2 stock 1 stock 2 stock 2 stock 3 stock 3 stock 5 stock 6 stock 8 stock 9	(First) (Middle)  IOS PHARMACEUTICALS, INC.  IEY STREET  Table I - Non-Deriv  Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  2. Table II - Derivative Security  (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  \$0.4675  02/05/2018	(First)	AGIOS   AGIO	AGIOS P   AGIO     3. Date of Earl 02/05/2018   4. If Amendment   Amendment	AGIOS PHARM   AGIO	AGIOS PHARMACE	AGIOS PHARMACEUT	AGIOS PHARMACEUTICALS   AGIO   3   Date of Earliest Transaction (Month/Day/Yei 02/05/2018   4   H Amendment, Date of Original Filed (Month Day/Yei 02/05/2018   4   H Amendment, Date of Original Filed (Month Day/Yei 02/05/2018   5   Code   V   Amount Date of Original Filed (Month Day/Yei Date Date Date Original Filed (Month Day/Yei Date Date Date Original Filed (Month Day/Yei Date Date Date Date Date Date Date Date	AGIOS PHARMACEUTICALS INC	AGIOS PHARMACEUTICALS INC   AGIO	AGIOS PHARMACEUTICALS INC   Check   AGIO   3. Date of Earliest Transaction (Month/Day/Year)   02/05/2018   4. If Amendment, Date of Original Filed (Month/Day/Year)   6. India Line)   X	AGIOS PHARMACEUTICALS INC   Check all apolic	AGIOS PHARMACEUTICALS INC   (Check all applicable)   Direction   Cofficer (give title below)   Direction   Chief Scient   Ch	AGIOS PHARMACEUTICALS INC   (First) (Middle)   (AGIO   AGIO   A

## Explanation of Responses:

- 1. This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 3. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$74.16 to \$75.06. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 4. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$75.31 to \$76.26. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 5. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$76.44 to \$77.20. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

- 6. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$77.63 to \$78.45. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 7. This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015.
- 8. This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.

## Remarks:

/s/ William Cook, as Attorney-<u>in-fact for Scott Biller</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.